Muscat – The factory, constructed with an investment exceeding RO 20 million, was opened on Monday, June 3, under the patronage of H.E. Dr. Hilal bin Ali Al Sabti, Minister of Health.
Covering an area of 12,000 square metres, the factory has been built in accordance with the specifications of the Ministry of Health and the US Food and Drug Administration (FDA) and in compliance with the European Medicines Agency (EMA). It is considered the first of its kind in the Middle East, manufacturing specialized and rare disease medicines.
The factory supports innovation and development, and aims to strengthen local supply chains and meet the needs of both the governmental and private health sectors in the Sultanate.
Menagen Pharmaceutical Industries is poised to deliver advanced international solutions to improve the quality of life and enhance health security in the region, by addressing the primary needs for medicines and medical supplies.
A prominent feature of the Menagen facility is its development and innovation center, the first of its kind in the region. This center is equipped to conduct preliminary studies and research and development activities, positioning Menagen as a leader in pharmaceutical innovation.
The health ministry also plans to open two additional pharmaceutical factories by the end of the year.
Read More
- India condemns Strait of Hormuz tanker attack, says one Indian missing
- Uzbek president concludes Oman state visit after signing strategic partnership pact
- Muscat Municipality announces National Day events at Al Khuwair Square
- Oman, Uzbekistan pursue preferential trade deal as they target $500 million in bilateral trade
- His Majesty Sultan Haitham, Uzbek president discuss closer ties in Muscat





